文献速递疼痛医学

慢性鞘内输注布比卡因治疗疼痛时的血清浓度观察研究

Bupivacaine serum concentrations during chronic intrathecal infusion for pain management: an observational single-center study.
PubMed 文献 · Reg Anesth Pain Med · 2026-09-08

该单中心回顾性研究纳入31例接受鞘内药物输注系统持续输注布比卡因治疗难治性癌痛的患者,共分析162份泵补充前血样。平均日剂量39.5 mg/day时平均血清浓度为167.7 µg/L,远低于公认的2 µg/mL毒性上限,且浓度与日剂量、体重指数及输注流速相关。

要点

  • 慢性鞘内布比卡因输注的全身暴露远低于2 µg/mL毒性阈值。
  • 血清布比卡因浓度与日剂量正相关,并受体重指数影响。
  • 校正日剂量后,较高输注流速仍独立关联更高的血清浓度。

核心结论

  • 慢性鞘内输注布比卡因用于癌痛管理时全身暴露远低于既定毒性阈值。

研究设计与样本

  • 单中心回顾性观察研究,纳入31例患者,共分析162份泵补充前血样,用自建方法检测布比卡因血浆浓度。

主要发现

  • 平均日鞘内布比卡因剂量为39.5 mg/day(SD 31.4 mg/day),平均血清浓度为167.7 µg/L(SD 266.2 µg/L)。
  • 血清布比卡因水平与日剂量正相关,并受体重指数影响。
  • 校正日剂量后,较高输注流速仍独立关联血清浓度升高。

关键数值与推荐

  • 预防全身毒性的血清最高浓度上限通常认为是2 µg/mL(2000 µg/L)。

临床怎么用

  • 癌痛患者慢性鞘内输注布比卡因时,可按日剂量与输注流速评估全身暴露风险。

局限性

  • 单中心回顾性设计,样本量31例,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intrathecal analgesia is recommended for the management of refractory cancer pain. Bupivacaine is the most commonly used local anesthetic in combination intrathecal therapies and is often administered at high doses. However, data on its systemic toxicity in this context remain limited. While the pharmacokinetics of bupivacaine have been described in epidural and spinal anesthesia, those studies involved substantially lower doses and minimal systemic absorption. A maximum serum concentration of 2 µg/mL (2000 µg/L) is generally considered the upper safety limit to prevent systemic toxicity, yet systemic exposure during chronic intrathecal infusion via an intrathecal drug delivery system has not been well characterized. METHODS: This single-center retrospective study aimed to quantify serum bupivacaine concentrations during intrathecal infusion and evaluate factors associated with systemic absorption. Serial bupivacaine plasma concentrations were measured with an in-house analytical assay on blood samples collected before each pump refill. RESULTS: Thirty-one patients were included, with a total of 162 blood samples analyzed. The mean daily intrathecal bupivacaine dose was 39.5 mg/day (SD 31.4 mg/day), resulting in a mean serum concentration of 167.7 µg/L (SD 266.2 µg/L). Serum bupivacaine levels were positively correlated with the daily dose and were also influenced by body mass index. After adjustment for daily dose, higher infusion flow rates remained independently associated with increased serum concentrations. CONCLUSION: Chronic intrathecal infusion of bupivacaine for cancer pain management results in systemic exposure well below the established toxicity threshold.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Bienfait F, Huchon-Petriolle A, Passot C, et al. Bupivacaine serum concentrations during chronic intrathecal infusion for pain management: an observational single-center study. Reg Anesth Pain Med. 2026. PMID: 42710943. doi:10.1136/rapm-2025-107216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。